Document Detail


Pregnancy and mefloquine prevention of malaria.
MedLine Citation:
PMID:  11475498     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
(1) Mefloquine is teratogenic in animals at high doses. (2) A prospective cohort study of several hundred women exposed to mefloquine at prophylactic doses (250 mg per week) in early pregnancy showed no increased risk of malformations. (3) Exposure to mefloquine in early pregnancy is not an indication for termination. (4) Data on exposure during the second or third trimester are reassuring. According to the World Health Organisation (WHO), the risk-benefit ratio of mefloquine prophylaxis is favourable in pregnant women from the fourth month of pregnancy onwards in areas of group III chemoresistance. (5) In France, mefloquine is contraindicated throughout pregnancy. In other countries mefloquine is approved from the first trimester to cover unavoidable visits to areas of group III chemoresistance.
Authors:
-
Related Documents :
24374868 - Ascites, anemia and (intestinal) atresia.
23752578 - Obstetric outcomes in the second birth of women with a previous caesarean delivery: a r...
23148678 - Clinical utility of serum reproductive hormones for the early diagnosis of ectopic preg...
23521828 - Clinical outcome after imsi procedure in an unselected infertile population: a pilot st...
10796268 - Treatments for toxoplasmosis in pregnancy.
15273828 - Enhanced expression of ang-(1-7) during pregnancy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  9     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-05-29     Completed Date:  2001-05-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  180-1     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced* / etiology
Animals
Antimalarials / adverse effects,  therapeutic use
Clinical Trials as Topic
Cohort Studies
Female
Humans
Infant, Newborn
Malaria / complications,  drug therapy,  prevention & control*
Mefloquine* / adverse effects,  therapeutic use
Mice
Pregnancy
Pregnancy Outcome*
Rats
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antimalarials; 53230-10-7/Mefloquine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pergolide and Parkinson's disease: new preparation. No clear benefit.
Next Document:  Think INN, prescribe INN, dispense INN: good professional practice.